Clinical Trials Browser

Active not recruiting × anlotinib × Clear all

NCT05685550 2026-02-05

Safety and Efficacy Analysis of Oral Etoposide Combined With Anlotinib and Envafolimab in First-line Treatment of Elderly Patients With Small Cell Lung Cancer/ Open-label, Single-arm, Exploratory Phase II Clinical Study

Phase 2 Active not recruiting

Progression Free Survival(PFS)

NCT07142421 2025-08-26

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

Phase 2 Active not recruiting

Gastrointestinal

Esophageal Squamous Cell Carcinoma

NCT04165330 2025-02-24

Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

Phase 1/2 Active not recruiting

SarcomaThoracic

Carcinoma, Non-Small-Cell Lung, Sarcoma, Small Cell Lung Carcinoma

NCT05400070 2024-10-18

Neoadjuvant PD-1 Inhibitor (Sintilimab), Anlotinib Combined With Chemotherapy in Resectable Stage IIA-IIIB NSCLC

Phase 2 Active not recruiting

Lung Neoplasms

NCT04523272 2024-10-15

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Sunitinib in Subjects With Advanced Renal Cancer

Phase 3 Active not recruiting

Advanced Renal Cancer

NCT04891900 2024-07-08

TQB2450 Plus Anlotinib Combined With Chemotherapy in the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma

Phase NA Active not recruiting

Gastrointestinal

Stomach Neoplasms

NCT04807166 2024-07-03

Anlotinib Combined With Carboplatin/Paclitaxel as First-line Treatment in Patients With Advanced Ovarian Cancer

Phase 2 Active not recruiting

Carcinoma, Ovarian Epithelial, Carcinoma, Endocrine System Diseases, Fallopian Tube Neoplasms, Genital Diseases, Female, Genital Neoplasms, Female, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Ovarian Diseases, Ovarian Neoplasms

NCT05816499 2024-06-17

AK104IIT018

Phase 1/2 Active not recruiting

Carcinoma, Non-Small-Cell Lung